ReviewFrontiers in pharmacology2026
Individualized dosing in the precision medicine era: a narrative review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individualized dosing has become a cornerstone of precision medicine by optimizing therapeutic efficacy while minimizing toxicity through patient-specific dose selection. Traditional approaches, including weight- and body surface area-based dosing, remain fundamental for many medications but are increasingly complemented by pharmacokinetic/pharmacodynamic (PK/PD)-guided strategies and model-informed precision dosing (MIPD). This narrative review summarizes current evidence on individualized dosing across four major therapeutic classes: antimicrobial agents, chemotherapy, monoclonal antibodies and immunotherapies, and anesthetic and critical care agents. It highlights the rationale, advantages, and limitations of conventional dosing approaches while discussing the growing adoption of fixed dosing for selected biologics with predictable pharmacokinetics. The review also examines practical challenges associated with individualized dosing, including dose calculation complexity, medication errors, and operational constraints. Finally, emerging precision-dosing strategies, particularly Bayesian adaptive dosing and biomarker-guided dosing, are discussed as promising approaches to further personalize pharmacotherapy. Collectively, these advances support a shift toward more precise, evidence-based, and patient-centered medication dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.